Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 15/20 | 1.00 |
| ▸ | CCNC | P24863 | 14/20 | 1.00 |
| ▸ | CDK19 | Q9BWU1 | 5/20 | 0.87 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.80 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.80 |
| ▸ | CDK1 | P06493 | 6/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30369547 | 1.00 | CDK8 (1.00) | CDK8CCNCCDK19MAP4K2HASPIN | |
| SCHEMBL21750436 | 0.93 | CDK8 (1.00) | CDK8CCNCCDK19MAP4K2HASPIN | |
| SCHEMBL31536433 | 0.90 | CDK8 (0.81) | CDK8CCNCCDK19MAP4K2HASPIN | |
| SCHEMBL25170660 | 0.90 | CDK8 (0.81) | CDK8CCNCCDK19MAP4K2HASPIN | |
| SCHEMBL30369589 | 0.90 | CDK8 (0.81) | CDK8CCNCCDK19MAP4K2HASPIN | |
| SCHEMBL25170646 | 0.90 | CDK8 (0.81) | CDK8CCNCCDK19MAP4K2HASPIN | |
| SCHEMBL25176412 | 0.90 | CDK8 (0.81) | CDK8CCNCCDK19MAP4K2HASPIN | |
| SCHEMBL25416194 | 0.90 | CDK8 (0.81) | CDK8CCNCCDK19MAP4K2HASPIN | |
| SCHEMBL30369629 | 0.90 | CDK8 (0.81) | CDK8CCNCCDK19MAP4K2HASPIN | |
| SCHEMBL30369655 | 0.90 | CDK8 (0.81) | CDK8CCNCCDK19MAP4K2HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281080-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2023081452-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20210276956-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210276956-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281080-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | CDK8, CDK9, CDK19 | CDK8 1/4885CCNC 35/4885CDK19 3/4885 |
| US-20210276956-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | CDK8, CDK9, CDK19 | CDK8 1/4885CCNC 34/4885CDK19 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.